ENDV · Endonovo Therapeutics, Inc. · Analyst Estimates
$0.00
At close · Nov 9
Return incl. dividend (before tax)
Going-concern doubt
— flagged Dec 29, 2023
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt as to its ability to continue as going concern within one year from issuance date of these unaudited consolidated financial statements.”View the 10-Q filed Dec 29, 2023
Market Cap
$31,875
Shares
318.75M
Volume · Nov 9
500K
Avg daily vol (3M)
753.37K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Analyst Estimates
Compare analyst forecasts for Endonovo Therapeutics, Inc. across metrics and forecast periods.
Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.
Pull consensus estimates through the analyst estimates API or MCP →Compiled consensus
These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.
Captured 2026-09-18 18:31 UTC · Publication dates shown per estimate · 1 metric / period groups
FY ending 2019-12-31
| Metric | Low | Average | High | Analyst count |
|---|---|---|---|---|
|
Revenue
Publication date not stated |
0.00
|
0.00
|
0.00
|
0
|